Mylonas and coworkers hypothesize that the HER-2 overexpression in tumors originated from atypical ductal hyperplasia (ADH) is more prominent than when derived from ductal carcinoma in situ (DCIS) [36]. The gene discussed is ERBB2; the disease is atypical ductal hyperplasia.